

BDNF Val66Met Impairs Fluoxetine-Induced Enhancement of Adult Hippocampus Plasticity

Kevin G Bath^{*,1,2}, Deqiang Q Jing¹, Iva Dincheva¹, Christine C Neeb¹, Siobhan S Pattwell¹, Moses V Chao³, Francis S Lee^{*,1,4} and Ipe Ninan^{*,5}

¹Department of Psychiatry, Weill Medical College of Cornell, New York, NY, USA; ²Department of Neuroscience, Brown University, Providence, RI, USA; ³Department of Cell Biology, Physiology and Neuroscience, and Psychiatry, The Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute for Biomolecular Medicine, New York University School of Medicine, New York, NY, USA; ⁴Department of Pharmacology, Weill Medical College of Cornell, New York, NY, USA; ⁵Department of Psychiatry, New York University School of Medicine, New York, NY, USA

Recently, a single-nucleotide polymorphism (SNP) in the *brain-derived neurotrophic factor* (BDNF) gene (BDNF Val66Met) has been linked to the development of multiple forms of neuropsychiatric illness. This SNP, when genetically introduced into mice, recapitulates core phenotypes identified in human BDNF Val66Met carriers. In mice, this SNP also leads to elevated expression of anxiety-like behaviors that are not rescued with the prototypic selective serotonin reuptake inhibitor (SSRI), fluoxetine. A prominent hypothesis is that SSRI-induced augmentation of BDNF protein expression and the beneficial trophic effects of BDNF on neural plasticity are critical components for drug response. Thus, these mice represent a potential model to study the biological mechanism underlying treatment-resistant forms of affective disorders. To test whether the BDNF Val66Met SNP alters SSRI-induced changes in neural plasticity, we used wild-type (BDNF^{Val/Val}) mice, and mice homozygous for the BDNF Val66Met SNP (BDNF^{Met/Met}). We assessed hippocampal BDNF protein levels, survival rates of adult born cells, and synaptic plasticity (long-term potentiation, LTP) in the dentate gyrus either with or without chronic (28-day) fluoxetine treatment. BDNF^{Met/Met} mice had decreased basal BDNF protein levels in the hippocampus that did not significantly increase following fluoxetine treatment. BDNF^{Met/Met} mice had impaired survival of newly born cells and LTP in the dentate gyrus; the LTP effects remained blunted following fluoxetine treatment. The observed effects of the BDNF Val66Met SNP on hippocampal BDNF expression and synaptic plasticity provide a possible mechanistic basis by which this common BDNF SNP may impair efficacy of SSRI drug treatment.

Neuropsychopharmacology advance online publication, 4 January 2012; doi:10.1038/npp.2011.318

Keywords: BDNF Val66Met SNP; hippocampus; neurogenesis; plasticity; fluoxetine; LTP

INTRODUCTION

Brain-derived neurotrophic factor (BDNF) is a critical regulator of activity-dependent plasticity in the adult brain (Barde *et al.*, 1987; Huang and Reichardt, 2001; Chao, 2003). Genetic or environmental factors that disrupt BDNF expression or signaling have been associated with the development of a number of neuropsychiatric disorders, including major depression (Okada *et al.*, 2006; Gatt *et al.*,

2009; Verhagen *et al.*, 2010). In rodent models, nearly all antidepressant regimens tested to date increase BDNF within the adult hippocampus (Duman and Monteggia, 2006; Musazzi *et al.*, 2009), a brain region heavily implicated in the expression of anxiety and depressive-like symptoms (Sahay and Hen, 2007). In rodents, the genetic ablation of BDNF leads to a blockade in the response to standard antidepressant regimens (Monteggia *et al.*, 2004; Adachi *et al.*, 2008). Furthermore, the infusion of BDNF protein into the brains of rodents has antidepressant effects (Siuciak *et al.*, 1997; Shirayama *et al.*, 2002). This has led some to propose that augmentation of BDNF expression via chronic antidepressant treatment, and the subsequent trophic effects of BDNF on neural plasticity, may be one of the critical mechanisms underlying antidepressant response.

The neurotrophic hypothesis of antidepressant response has become particularly relevant given the recent discovery of a uniquely human single-nucleotide polymorphism (SNP) in the *BDNF* gene (BDNF Val66Met; Egan *et al.*, 2003). This SNP leads to a nucleotide change from G to A at

*Correspondence: Dr FS Lee, Department of Psychiatry, Weill Medical College of Cornell University, Weill Cornell Medical College, 1300 York Avenue (LC-905), Box 244, New York, NY 10021, USA, Tel: +1 212 746 5403, Fax: +1 212 746 8529, E-mail: fslee@med.cornell.edu or Dr I Ninan, Department of Psychiatry, New York University School of Medicine, 540 1Ave, SKI 5-3, New York NY 10016, USA, Tel: +1 347 535 0710, Fax: +1 212 263 0723, E-mail: lpe@Ninan.nyumc.org or Dr KG Bath, Department of Neuroscience, Brown University, 185 Meeting Street, Providence, RI 02916, USA, Tel: +1 401 863 1054, E-mail: Kevin_Bath@Brown.edu

Received 5 August 2011; revised 28 October 2011; accepted 17 November 2011

position 196 and subsequent amino acid change at position 66 in the BDNF prodomain, from valine to methionine, and interferes with the trafficking of BDNF mRNA (Chiaruttini *et al.*, 2009), as well as a selective impairment in the activity-dependent release of BDNF (Egan *et al.*, 2003; Chen *et al.*, 2004, 2005, 2006). Human carriers of this SNP have impairments in hippocampus-dependent memories and the extinction of learned fear (Egan *et al.*, 2003; Soliman *et al.*, 2010). Male BDNF Val66Met carriers have been shown to be at increased risk to develop depression, an effect that has recently been confirmed by the largest meta-analysis to date (Verhagen *et al.*, 2010). In addition, carriers of the BDNF Val66Met SNP that develop depression often demonstrate more severe symptoms than individuals who are non-carriers (Hwang *et al.*, 2006; Iga *et al.*, 2007; Sarchiapone *et al.*, 2008; Verhagen *et al.*, 2010). Despite these findings, significant questions remain regarding the mechanisms underlying BDNF's contribution to the development of affective disorders and the potential role of this SNP in treatment response (Tsai *et al.*, 2010). Animal models have provided a fruitful testing ground to address such questions.

We have generated a mouse model in which we knocked-in the BDNF Val66Met SNP into the mouse *bdnf* gene, replacing the endogenous BDNF. Mice homozygous for the BDNF Val66Met SNP (BDNF^{Met/Met}) phenocopy human SNP carriers (Chen *et al.*, 2006; Soliman *et al.*, 2010) and have elevated expression of anxiety-like behaviors that are unresponsive to chronic treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Thus, this mouse may provide a model system to gain insights into the mechanisms by which BDNF Val66Met suppresses the response of some individuals to SSRI treatment.

In animal models of depression, two of the potential targets of increased trophic support are through augmentation of hippocampal neurogenesis (Castren, 2004; Sahay and Hen, 2007; Schmidt and Duman, 2007) and synaptic plasticity (Manji *et al.*, 2003; Castren, 2004; Russo-Neustadt and Chen, 2005; Wang *et al.*, 2008), both processes are impacted by altered BDNF levels (Figurov *et al.*, 1996; Sairanen *et al.*, 2005; Scharfman *et al.*, 2005; Chan *et al.*, 2008; Donovan *et al.*, 2008; Li *et al.*, 2008). We found that BDNF^{Met/Met} mice had decreased basal levels of BDNF in the hippocampus, and unlike BDNF^{Val/Val} mice, BDNF protein levels did not increase following chronic fluoxetine treatment. We tested for alterations in the functional plasticity of the hippocampus under basal conditions and following chronic fluoxetine treatment in BDNF^{Met/Met} and BDNF^{Val/Val} mice. BDNF^{Met/Met} mice also had fewer surviving newly born cells in the adult dentate gyrus (DG) of the hippocampus relative to BDNF^{Val/Val} controls. Following fluoxetine treatment, neurogenesis in BDNF^{Met/Met} mice normalized to untreated wildtype levels. Finally, we found impairments in long-term potentiation (LTP) in the DG of BDNF^{Met/Met} mice compared with BDNF^{Val/Val} controls, an effect that was not rescued by chronic fluoxetine treatment. These studies are the first to identify impairments in BDNF protein expression, the incorporation of newly born cells, and synaptic plasticity in the DG of adult BDNF^{Met/Met} mice. Furthermore, these studies provide a possible mechanistic framework through which the BDNF Val66Met SNP could impair SSRI response.

MATERIALS AND METHODS

Mice

All mice used in these studies were adult males (3–4 months of age), housed in standard shoebox cages on a 12:12 reverse light/dark schedule. BDNF knockout mice as described in (Lyons *et al.*, 1999) and TrkB knockout mice as described in (Klein *et al.*, 1989) along with wild-type littermate controls were also used for cell survival studies. For the remainder of studies, BDNF Val66Met knock-in mice (BDNF^{Met/Met}) and wild-type (BDNF^{Val/Val}) littermate controls as described in (Chen *et al.*, 2006) were used. All mouse lines were fully backcrossed (minimum of 10 generations) onto an inbred C57BL/6 background. Animal care was in accordance with Weill Medical College of Cornell University IACUC and FDA standards.

Tissue Preparation and Immunohistochemistry

Control and genetically modified lines of mice were deeply anesthetized with pentobarbital and transcardially perfused with a solution of 0.9% saline and 0.1% sodium nitrite followed by 4% paraformaldehyde in phosphate buffer. Brains were dissected out and postfixed in 4% paraformaldehyde for 1 h. Brains were then incubated in a 30% sucrose solution overnight at 4°C. Coronal sections were serially cut at 40 µm using a freezing microtome. Immunohistochemistry was performed on floating sections. Briefly, sections were first incubated in a blocking solution for 1 h and then transferred to the primary antibody solution for 48 h at 4°C before incubation with the corresponding fluorescent-labeled (Invitrogen, Carlsbad, CA) or biotinylated secondary antibody (Vector Laboratories, Burlingame, CA). Antibodies and dilutions used included a rabbit polyclonal anti-pTrkB (1:500), anti-NeuN (Millipore; 1:1000), anti-polysialylated neural cell adhesion molecule (PSA-NCAM; Millipore; 1:400), anti-GFAP (Millipore; 1:1000), anti-BrdU (BD Biosciences; 1:200). BrdU-labeled sections were analyzed using a standard Nikon (Tokyo, Japan) upright microscope, digital camera mount, and the MetaMorph software package (Molecular Devices, Sunnyvale, CA). For co-labeling studies we performed confocal fluorescence microscopy using a Zeiss (Oberkochen, Germany) LSM510 microscope fitted with a Zeiss ×63 1.4 numerical aperture objective with standard filter sets and a standard (1 Airy disk) pinhole.

Fluoxetine Administration

Fluoxetine was dissolved in water (160 mg/l, as described in (Dulwala *et al.*, 2004)) and administered in light-protected water bottles. Fluoxetine infused water was changed every 72 h to insure fresh and active drug. Inclusion of fluoxetine led to no change in water consumption, and based on the average daily water intake of mice (3.1 ml per mouse, per day with a range of 2.5–3.8 ml), this concentration led to an average daily dose of 0.5 mg of fluoxetine per day (or ~16 mg/kg). This dosing regimen has been shown to lead to therapeutic levels in blood and to be highly effective in reducing anxiety-like symptoms in standard inbred mouse strains (Dulwala *et al.*, 2004; Dulwala and Hen, 2005).

BDNF ELISA

To measure endogenous BDNF levels, a BDNF enzyme-linked immunosorbent assay (ELISA) was used (BDNF Emax Immunoassay System, Promega, Madison, WI) with recombinant BDNF as a standard. This methodology demonstrates low cross-reactivity (<3%) with other neurotrophic factors and is capable of detecting a minimum of 15.6 pg/ml of BDNF. Briefly, control and fluoxetine treated BDNF^{Val/Val} and BDNF^{Met/Met} mice were killed by cervical dislocation and then decapitation. Brains were collected on ice and total bilateral hippocampi were dissected and then lysed in 700 μ l TNE lysis buffer (0.1 M Tris HCl, 0.15 M NaCl, 0.001 M EDTA, 1% NP-40). Lysates were centrifuged for 10 min at 4°C and the clarified supernatant was collected. Using the Bradford method, total levels of protein were quantified. Tissue and assay were prepared and run in accordance with the manufacturers suggested protocol. BDNF levels were then corrected based on the total amount of protein loaded.

BrdU Labeling, Detection, and Quantification

BrdU labeling and immunohistochemical detection was carried out as described in Bath *et al.* (2008). To quantify the density of BrdU positive cells in the sub-granular & granule cell layer of the DG, a profile counting method was used (described below). To estimate the rate of survival of newly born cells, mice were given a single injection of BrdU (160 mg/kg) and allowed to survive for 4-weeks prior to sacrifice. To avoid double counting, every third serially obtained section (80 μ m interval) and was counterstained with Nissl to allow discrimination of individual cells that may be clustered. All BrdU-positive nuclei within the granule cell layer of the DG were counted. The total number of counted cells was then divided into the total volume measured in order to obtain an estimate of the density of BrdU positive cells within this structure.

LTP and Basal Transmission in DG

Control or fluoxetine treated mice were killed by decapitation after pentobarbital anesthesia. Brains were quickly removed and placed in ice-cold artificial cerebrospinal fluid (ACSF) consisting of (in mM): NaCl (118), KCl (4.4), CaCl₂ (2), MgCl₂ (2), NaHCO₃ (26), NaH₂PO₄ (1), D-glucose (10) aerated by 95% O₂/ 5% CO₂ (pH 7.4; Ninan *et al.*, 2010). Hippocampi were quickly removed. Transverse hippocampal slices (400 μ m) were cut and transferred to a slice pre-incubator (Scientific System Design, Canada) at room temperature for at least 1-h to allow for recovery. A single slice was then transferred to an interface-recording chamber maintained at 32 °C (Scientific System Design, Canada). The chamber was continuously perfused by ACSF at a constant rate of 2 ml/min. Recording electrodes were filled with 2 M NaCl solution and field excitatory postsynaptic potentials (fEPSPs) were recorded from the molecular layer of the DG with IE-210 amplifier (Warner Instruments, USA) using Digidata 1440A and pClamp 10 software (Molecular Devices, USA). The stimulating electrode (concentric bipolar electrodes, FHC, Bowdoinham, ME) was placed in the medial perforant path (MPP) and stimulated using a

Digital stimulator PG4000A (Cygnus Technology, PA) and stimulus isolator A365 (World Precision Instruments, Sarasota, FL). MPP-DG pathway was confirmed by assessing paired-pulse depression (PPD) at 50 ms inter-pulse interval (McNaughton, 1980; Wang *et al.*, 2008). After obtaining stable basal recording, input-output curves were generated. A 15-minute baseline was recorded every 20 s at an intensity that evoked a response approximately 35% of the maximum evoked response. LTP was induced using 100 Hz stimulation (4 trains, 100 Hz for 1 min, separated by 20 s). Responses were recorded for 1 h after tetanization and measured fEPSP slope expressed as percentage of baseline.

Statistics

For comparisons in which greater than two groups were included, a one-way analysis of variance (ANOVA) was used. In the event of a significant main effect, *post hoc* group comparisons were made using a least significant differences (LSD) approach, correcting for multiple tests. In cases in which two-groups were compared, we used Student's *t*-test. For all statistics α -value was set at <0.05. SPSS software (IBM) was used for all analyses.

RESULTS

Chronic Fluoxetine Fails to Normalize Hippocampal BDNF Levels in BDNF^{Met/Met} Mice

In rodent models, nearly all antidepressant regimens tested to date have been shown to increase BDNF protein levels in the hippocampus and other brain regions (Duman and Monteggia, 2006), an effect implicated in antidepressant efficacy. To test if the BDNF Val66Met polymorphism affects basal or SSRI-related augmentation of hippocampal BDNF protein levels in mice, we used a BDNF ELISA. We found a significant main effect of group (ANOVA, $F_{(3,35)} = 6.058$, $p < 0.002$). More specifically, we found that BDNF protein levels in untreated BDNF^{Met/Met} mice were significantly lower than that observed in untreated wild-type (BDNF^{Val/Val}) mice (*post hoc* LSD, $p < 0.01$; Figure 1). As anticipated, following 28-days of fluoxetine treatment,




Figure 1 Bar graphs depicting BDNF protein levels (pg/mg of protein) in hippocampal lysates from adult wild-type (control $n = 11$, fluox $n = 11$; BDNF^{Val/Val}) and BDNF Val66Met homozygous (control $n = 9$, fluox $n = 11$; BDNF^{Met/Met}) mice maintained for 28 days on water (Control) or 160 mg/l fluoxetine (Fluox); * indicates significant difference, $p < 0.05$. N.S., not significant difference.

BDNF^{Val/Val} mice showed a significant increase in BDNF protein levels compared with untreated BDNF^{Val/Val} controls (*post hoc* LSD, $p < 0.01$; Figure 1). Interestingly, fluoxetine treatment did not increase BDNF protein expression in BDNF^{Met/Met} mice above levels observed in untreated BDNF^{Met/Met} controls (*post hoc* LSD, $p > 0.05$) and remained significantly lower than that observed in untreated BDNF^{Val/Val} mice (*post hoc* LSD, $p < 0.05$).

Altered BDNF and TrkB Expression Decrease Basal Rates of Cell Survival in the Adult DG

In previous reports, the genetic ablation of BDNF or TrkB in mice leads to a selective loss of surviving newly born but not proliferating cells of the DG (Bergami *et al.*, 2008; Chan *et al.*, 2008; Bergami *et al.*, 2009; Gao and Chen, 2009). Furthermore, during neurogenesis, the BDNF receptor, TrkB, is selectively expressed by postmitotic neuroblasts and neurons (Donovan *et al.*, 2008). The loss of BDNF alters the neuronal fate of these cells and leads to decreased dendritic complexity of differentiated DG neurons (Chan *et al.*, 2008). Using immunohistochemical labeling for the phosphorylated form of TrkB (pTrkB), we found pTrkB to be most highly expressed on immature (PSA-NCAM-positive) neuroblasts (Bath *et al.*, 2008). In the rostral migratory stream pTrkB expression was not detectable on GFAP-positive or NeuN-positive cells (Bath *et al.*, 2008). These effects were identical to what we observed in the DG (Supplementary Figure 1). On the basis of these observations, we focused our investigation of BDNF-mediated effects following fluoxetine treatment upon measures of cell survival within the DG.

We used BrdU labeling (Supplementary Figure 2) to test if altered BDNF or TrkB expression impacts the survival of newly born cells of the adult DG. Consistent with previous reports (Sairanen *et al.*, 2005; Chan *et al.*, 2008), the density of BrdU-positive cells in the DG of heterozygous BDNF knock-out mice (BDNF^{+/-}) was significantly lower than that observed in wild-type littermate controls (BDNF^{+/+}; Student's *t*-test, $t(6) = 5.74$, $p < 0.01$; Figure 2a). Similarly, genetic ablation of one copy of the *trkb* gene (TrkB^{+/-}) resulted in a significant reduction in the density of surviving newly born granule cells in the DG (Student's *t*-test, $t(6) = 2.44$, $p < 0.05$; Figure 2b) compared with wild-type littermate controls (TrkB^{+/+}). For mice in which the

BDNF Val66Met SNP was genetically knocked-in, we found a main effect of genotype (ANOVA, $F_{(2,9)} = 2.939$, $p < 0.05$; see Supplementary Figure 3); BDNF^{Met/Met} mice had a significant reduction in the density of surviving BrdU-labeled cells compared with BDNF^{Val/Val} mice (*Post Hoc* LSD, $p < 0.05$; Figure 2c).

Impact of Chronic Fluoxetine on Cell Survival in the DG of BDNF^{Met/Met} Mice

Chronic antidepressant treatment has been shown to augment the survival of newly born cells in the adult DG (Castren, 2004). To test whether the BDNF Val66Met polymorphism altered the antidepressant-induced increase in cell survival, we again used BrdU labeling to track cell survival. We found a significant main effect of group (ANOVA, $F_{(3,20)} = 6.257$, $p < 0.01$; Figure 3). We noted a significant difference in basal rates of neurogenesis between BDNF^{Val/Val} and BDNF^{Met/Met} mice, with BDNF^{Met/Met} mice having fewer surviving BrdU-positive cells (*post hoc* LSD, $p < 0.05$). Chronic fluoxetine led to a significant increase in the survival of newly born cells in both BDNF^{Val/Val} (*post hoc* LSD, $p < 0.05$) and BDNF^{Met/Met} mice (*post hoc* LSD, $p < 0.05$) compared with untreated control groups.




Figure 3 Bar graphs depicting BrdU cell density (cells/mm³) in the DG of adult mice 28 days following BrdU administration in the DG adult BDNF^{Val/Val} ($n = 6$ per group) and BDNF^{Met/Met} ($n = 6$ per group) mice maintained for 28 days on water (Control) or 160 mg/l fluoxetine (Fluox); * indicates significant difference, $p < 0.05$. N.S., not significant difference.




Figure 2 Bar graphs depicting BrdU cell density (cells/mm³) in the dentate gyrus of adult mice 28 days following BrdU injection in (a) BDNF wild-type ($n = 4$; BDNF^{+/+}) and BDNF heterozygous ($n = 4$; BDNF^{+/-}) mice, (b) TrkB wild-type ($n = 4$; TrkB^{+/+}) and TrkB heterozygous ($n = 4$; TrkB^{+/-}) mice. BrdU cell density (cells/mm³) (c) in BDNF^{Val/Val} ($n = 5$) and BDNF^{Met/Met} ($n = 5$) mice; * indicates significant difference, $p < 0.05$.

BDNF^{Met/Met} Impairs Synaptic Plasticity Within the Dentate Gyrus

Earlier studies have demonstrated that chronic fluoxetine treatment can enhance synaptic neurotransmission and plasticity in the DG (Wang *et al.*, 2008). We tested whether the BDNF Val66Met polymorphism interfered with the fluoxetine-induced enhancement of synaptic transmission (fEPSP) and synaptic plasticity (LTP) in the DG. We analyzed PPD to confirm the MPP-DG pathway and to determine whether this short-term plasticity was modified by the BDNF Val66Met polymorphism or fluoxetine treatment (McNaughton, 1980; Wang *et al.*, 2008). Although we did not observe a difference in PPD between BDNF^{Met/Met} and BDNF^{Val/Val} mice, fluoxetine treatment decreased PPD in BDNF^{Val/Val} mice (ANOVA followed by *post hoc* comparison, $p < 0.05$, Figure 4a). Our results are consistent with the earlier report that chronic fluoxetine decreased PPD at the MPP-DG synapses and this effect

might be independent of neurogenesis (Wang *et al.*, 2008). However, the suppression of PPD in fluoxetine-treated BDNF^{Met/Met} did not reach statistical significance (ANOVA followed by *post hoc* comparison, $p > 0.05$). Input-output relationship analysis of fEPSP slope revealed no significant differences in basal synaptic neurotransmission between untreated BDNF^{Met/Met} and matched BDNF^{Val/Val} mice (Two-way ANOVA, $p > 0.05$, Figure 4b). Although fluoxetine treatment induced a robust enhancement of basal synaptic neurotransmission in the BDNF^{Val/Val} mice (Two-way ANOVA, $F_{(1,14)} = 14.5$, $p < 0.01$, Figure 4b), fluoxetine-treated BDNF^{Met/Met} mice revealed a slight but statistically nonsignificant enhancement of basal synaptic neurotransmission compared with the untreated mice ($p > 0.05$, Figure 4b). As the long-lasting potentiation in the MPP-DG pathway in the absence of GABA blockers is sensitive to the incorporation of new cells into the hippocampus (Snyder *et al.*, 2001; Saxe *et al.*, 2006; Wang *et al.*, 2008), we hypothesized that impaired survival of newly




Figure 4 Effect of fluoxetine treatment on synaptic neurotransmission and plasticity in the DG. (a) PPD of fEPSPs in BDNF^{Val/Val} ($n = 10$), BDNF^{Met/Met} ($n = 8$), fluoxetine + BDNF^{Val/Val} ($n = 10$) and fluoxetine + BDNF^{Met/Met} groups ($n = 8$). Fluoxetine treatment suppressed the PPD in BDNF^{Val/Val} mice but not in BDNF^{Met/Met} mice. (b) Input-output curves of fEPSPs in BDNF^{Val/Val} ($n = 10$), BDNF^{Met/Met} ($n = 8$), fluoxetine + BDNF^{Val/Val} ($n = 10$) and fluoxetine + BDNF^{Met/Met} groups ($n = 8$). Fluoxetine treatment induced a robust enhancement of basal synaptic neurotransmission in the BDNF^{Val/Val} mice but not in BDNF^{Met/Met} mice. (c) LTP in BDNF^{Val/Val} ($n = 10$), BDNF^{Met/Met} ($n = 8$), fluoxetine + BDNF^{Val/Val} ($n = 10$) and fluoxetine + BDNF^{Met/Met} groups ($n = 8$). LTP was significantly impaired in the BDNF^{Met/Met} mice. Fluoxetine selectively enhanced LTP in the BDNF^{Val/Val} mice but not in the BDNF^{Met/Met} mice.

born cells in the BDNF^{Met/Met} mice could interfere with fluoxetine-induced enhancement of long-lasting potentiation in the MPP-DG pathway. Consistent with the earlier reports (Snyder *et al.*, 2001; Saxe *et al.*, 2006; Wang *et al.*, 2008), application of a 100 Hz stimulus (4 trains, 100 Hz for 1 min, separated by 20 s) induced long-lasting potentiation in the untreated BDNF^{Val/Val} mice (Figure 4c). However, the long-lasting potentiation in the BDNF^{Met/Met} mice was significantly lower than that observed in BDNF^{Val/Val} mice (Two-way ANOVA, $F_{(1,16)} = 24.4$, $p < 0.01$, Figure 4c). Although fluoxetine treatment significantly enhanced long-lasting potentiation in the BDNF^{Val/Val} mice (Two-way ANOVA, $F_{(1,18)} = 8.6$, $p < 0.01$, Figure 4c), the BDNF^{Met/Met} mice did not show any significant improvement in long-lasting potentiation after fluoxetine treatment compared with untreated BDNF^{Met/Met} controls (Two-way ANOVA, $p > 0.05$, Figure 4c).

DISCUSSION

In this report, we provide the first mechanistic links between the BDNF Val66Met polymorphism and SSRI drug resistance. We found that BDNF^{Met/Met} mice had decreased basal levels of hippocampal BDNF and did not show antidepressant-induced augmentation of BDNF protein levels. BDNF^{Met/Met} mice had impairments in the survival of newly born cells in the DG, an effect that was normalized to control wild-type levels by SSRI treatment. Finally, we observed a blunting of synaptic plasticity within the DG of BDNF^{Met/Met} mice, an effect that could not be rescued with the SSRI fluoxetine. These studies identify several potential mechanisms underlying blunted treatment response in mice that are homozygous for the BDNF Val66Met SNP, and may have implications for understanding mechanisms underlying treatment non-responsiveness in human populations.

Under baseline conditions, BDNF^{Met/Met} mice had significantly lower BDNF protein levels in the hippocampus compared with control BDNF^{Val/Val} mice. In previous reports, we have shown that the BDNF Val66Met SNP does not lead to a reduction in total BDNF levels in the whole brain of BDNF^{Met/Met} mice, cultured cortical neurons from BDNF^{Met/Met} mice (Chen *et al.*, 2006), or cortical tissues (Bath *et al.*, 2008). This SNP does lead to a decrease in the trafficking of BDNF to secretory vesicles and the subsequent activity-dependent release of BDNF (Egan *et al.*, 2003; Chen *et al.*, 2004, 2005). As the hippocampus is target of many cortical and subcortical projections, the decreased levels of BDNF could in part be due to decreased BDNF secretion from afferent inputs to the hippocampus. In recent reports, the BDNF Val66Met SNP has also been shown to impact trafficking of BDNF mRNA to dendritic processes where it can be locally transcribed (Chiaruttini *et al.*, 2009). Reduced transport and local translation of BDNF mRNA in BDNF^{Met/Met} mice may also contribute to the lower protein expression observed in the hippocampus. Such effects may contribute to previously described alterations in dendritic complexity of hippocampal neurons of BDNF^{Met/Met} mice (Chen *et al.*, 2006). However, further studies are required to fully understand the basis of this marked decrease in basal hippocampal BDNF protein levels.

BDNF^{Met/Met} mice had significantly fewer surviving newly born cells in the DG compared with BDNF^{Val/Val} mice. Disruptions in neurogenesis have been reliably linked with the development of anxiety-like behavior and antidepressant response in animal models of anxiety and depressive-like disorders (Santarelli *et al.*, 2003). Here we demonstrate that cell survival is impaired in the DG of BDNF^{Met/Met} mice, an effect that is correlated with their development of anxiety-like behaviors. We further show that SSRI's can significantly potentiate the survival of cells in the DG of BDNF^{Met/Met} mice. These data could suggest that SSRI-induced augmentation in newly born cell survival may not be critical for the behavioral effects of antidepressants in BDNF^{Met/Met} mice. Alternatively, animals that have had a chronic blunting in the survival of adult born cells throughout life may simply not benefit from the modest yet significant increase in cell survival (eg the degree to which cell survival increased may have been simply insufficient).

We have shown that the BDNF Val66Met SNP leads to decreased trafficking of BDNF into secretory granules (Chen *et al.*, 2004, 2005) and thus a reduction in the activity-dependent release of BDNF (Egan *et al.*, 2003; Chen *et al.*, 2005, 2006). In BDNF Val66Met mice, we anticipate that the reduced activity-dependent release of BDNF onto immature cells and thus a decrease in critical trophic support during the process of cellular differentiation is the critical underlying factor leading to decreased survival of newly born cells. Such findings are consistent with previously published reports demonstrating that the genetic or pharmacological ablation of BDNF results in decreased adult neurogenesis within the hippocampus (Sairanen *et al.*, 2005; Chan *et al.*, 2008; Choi *et al.*, 2009), with specific effects on the maturation and survival of newly born neurons and the selective expression and activation of the BDNF receptor TrkB on postmitotic neuroblasts.

We uncovered significant impairments in synaptic plasticity in the dentate gyrus of BDNF^{Met/Met} mice, under both basal conditions and following chronic fluoxetine treatment. We have recently described significant effects of this SNP on synaptic transmission and plasticity at the CA3-CA1 synapse (Ninan *et al.*, 2010). To our knowledge, these are the first studies to identify impairments in synaptic plasticity resulting from the BDNF Val66Met SNP in the DG. On the basis of our observations, SSRI-induced augmentations in LTP were completely blocked in BDNF^{Met/Met} mice an effect that parallels the failure of these mice to show behavioral benefits of antidepressant treatment. Despite the rescue of neurogenesis to control levels, fluoxetine failed to reverse LTP impairment in BDNF^{Met/Met} mice. These results suggest that fluoxetine affects plasticity by mechanisms other than neurogenesis. The lack of effect of fluoxetine on BDNF levels or a potential alteration of synaptic function might be responsible for fluoxetine-resistant LTP impairment in BDNF^{Met/Met} mice (Colino and Malenka, 1993; Ninan *et al.*, 2010). BDNF has reliably been shown to be a significant promoter of synaptic excitability and LTP within the hippocampus (Minichiello, 2009) and the loss of TrkB from newborn neurons in this region significantly impact LTP (Bergami *et al.*, 2008). We hypothesize that the observed effects of BDNF^{Met/Met} on synaptic functions are in large part due to a general

decrease in the availability of BDNF in BDNF^{Met/Met} mice as a result of impairments in activity dependent BDNF secretion. However, given the potential impact of this SNP on trafficking of BDNF mRNA to dendrites, we cannot rule out the potential role of alterations in postsynaptic BDNF expression as a contributing factor to this effect.

In conclusion, these findings provide some of the first mechanistic links between the BDNF Val66Met SNP and the development of SSRI-resistant anxiety-like behaviors. Thus, these mice may provide a useful model system to test novel therapeutic strategies to rescue anxiety and depressive-like symptoms that are unresponsive to standard drug regimens. Furthermore, such a model system may be important for understanding the mechanisms underlying treatment response to common antidepressant and anxiolytic drugs and the contribution of genetic variation to treatment outcome.

ACKNOWLEDGEMENTS

This work was supported by the Sackler Institute (K.G.B.), DeWitt-Wallace Fund of the New York Community Trust (F.S.L.), Irma T. Hirschl/Monique Weill-Caulier Trust (F.S.L.), International Mental Health Research Organization (F.S.L.), Burroughs Wellcome Foundation (FSL), Pritzker Consortium (F.S.L.), Brain & Behavior Research Foundation-NARSAD (I.N., K.G.B., F.S.L.), and National Institutes of Health grants HD055177 (S.S.P.), NS21072 (M.V.C.), MH060478 (K.G.B.), NS052819 (F.S.L.), and MH088814 (F.S.L.).

DISCLOSURE

None of the authors report biomedical financial interests or potential conflicts of interest. The authors declare that over the past year, FSL has received compensation as a consultant for Ono Pharmaceuticals.

REFERENCES

Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM (2008). Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. *Biol Psychiatry* **63**: 642–649.

Barde YA, Davies AM, Johnson JE, Lindsay RM, Thoenen H (1987). Brain derived neurotrophic factor. *Prog Brain Res* **71**: 185–189.

Bath KG, Mandairon N, Jing D, Rajagopal R, Kapoor R, Chen ZY *et al.* (2008). Variant brain-derived neurotrophic factor (Val66-Met) alters adult olfactory bulb neurogenesis and spontaneous olfactory discrimination. *J Neurosci* **28**: 2383–2393.

Bergami M, Berninger B, Canossa M (2009). Conditional deletion of TrkB alters adult hippocampal neurogenesis and anxiety-related behavior. *Commun Integr Biol* **2**: 14–16.

Bergami M, Rimondini R, Santi S, Blum R, Gotz M, Canossa M (2008). Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. *Proc Natl Acad Sci USA* **105**: 15570–15575.

Castren E (2004). Neurotrophic effects of antidepressant drugs. *Curr Opin Pharmacol* **4**: 58–64.

Chan JP, Cordeira J, Calderon GA, Iyer LK, Rios M (2008). Depletion of central BDNF in mice impedes terminal differentiation of new granule neurons in the adult hippocampus. *Mol Cell Neurosci* **39**: 372–383.

Chao MV (2003). Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nat Rev Neurosci* **4**: 299–309.

Chen ZY, Ieraci A, Teng H, Dall H, Meng CX, Herrera DG *et al.* (2005). Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. *J Neurosci* **25**: 6156–6166.

Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ *et al.* (2006). Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. *Science* **314**: 140–143.

Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL *et al.* (2004). Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. *J Neurosci* **24**: 4401–4411.

Chiaruttini C, Vicario A, Li Z, Baj G, Braiuca P, Wu Y *et al.* (2009). Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. *Proc Natl Acad Sci USA* **106**: 16481–16486.

Choi SH, Li Y, Parada LF, Sisodia SS (2009). Regulation of hippocampal progenitor cell survival, proliferation and dendritic development by BDNF. *Mol Neurodegener* **4**: 52.

Colino A, Malenka RC (1993). Mechanisms underlying induction of long-term potentiation in rat medial and lateral perforant paths *in vitro*. *J Neurophysiol* **69**: 1150–1159.

Donovan MH, Yamaguchi M, Eisch AJ (2008). Dynamic expression of TrkB receptor protein on proliferating and maturing cells in the adult mouse dentate gyrus. *Hippocampus* **18**: 435–439.

Dulwala SC, Hen R (2005). Recent advances in animal models of chronic antidepressant effects: the novelty induced hypophagia test. *Neurosci Biobehav Rev* **29**: 771–783.

Dulwala SC, Holick KA, Gundersen B, Hen R (2004). Effects of chronic fluoxetine in animal models of anxiety and depression. *Neuropsychopharmacology* **29**: 1321–1330.

Duman RS, Monteggia LM (2006). A neurotrophic model for stress-related mood disorders. *Biol Psychiatry* **59**: 1116–1127.

Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A *et al.* (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* **112**: 257–269.

Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B (1996). Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. *Nature* **381**: 706–709.

Gao X, Chen J (2009). Conditional knockout of brain-derived neurotrophic factor in the hippocampus increases death of adult-born immature neurons following traumatic brain injury. *J Neurotrauma* **26**: 1325–1335.

Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR *et al.* (2009). Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. *Mol Psychiatry* **14**: 681–695.

Huang EJ, Reichardt LF (2001). Neurotrophins: roles in neuronal development and function. *Annu Rev Neurosci* **24**: 677–736.

Hwang JP, Tsai SJ, Hong CJ, Yang CH, Lirng JF, Yang YM (2006). The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. *Neurobiol Aging* **27**: 1834–1837.

Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S *et al.* (2007). The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with psychotic feature and suicidal behavior in Japanese major depressive patients. *Am J Med Genet B Neuropsychiatr Genet* **144B**: 1003–1006.

- Klein R, Parada LF, Coulier F, Barbacid M (1989). trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. *EMBO J* 8: 3701–3709.
- Li Y, Luikart BW, Birnbaum S, Chen J, Kwon CH, Kernie SG *et al*. (2008). TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressant treatment. *Neuron* 59: 399–412.
- Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, Bora SH *et al*. (1999). Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. *Proc Natl Acad Sci USA* 96: 15239–15244.
- Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray AN *et al*. (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. *Biol Psychiatry* 53: 707–742.
- McNaughton BL (1980). Evidence for two physiologically distinct perforant pathways to the fascia dentata. *Brain Res* 199: 1–19.
- Minichiello L (2009). TrkB signalling pathways in LTP and learning. *Nat Rev Neurosci* 10: 850–860.
- Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T *et al*. (2004). Essential role of brain-derived neurotrophic factor in adult hippocampal function. *Proc Natl Acad Sci USA* 101: 10827–10832.
- Musazzi L, Cattaneo A, Tardito D, Barbon A, Gennarelli M, Barlati S *et al*. (2009). Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. *BMC Neurosci* 10: 48.
- Ninan I, Bath KG, Dagar K, Perez-Castro R, Plummer MR, Lee FS *et al*. (2010). The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. *J Neurosci* 30: 8866–8870.
- Okada T, Hashimoto R, Numakawa T, Iijima Y, Kosuga A, Tatsumi M *et al*. (2006). A complex polymorphic region in the brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity. *Mol Psychiatry* 11: 695–703.
- Russo-Neustadt AA, Chen MJ (2005). Brain-derived neurotrophic factor and antidepressant activity. *Curr Pharm Des* 11: 1495–1510.
- Sahay A, Hen R (2007). Adult hippocampal neurogenesis in depression. *Nat Neurosci* 10: 1110–1115.
- Sairanen M, Lucas G, Ernfors P, Castren M, Castren E (2005). Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. *J Neurosci* 25: 1089–1094.
- Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S *et al*. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science* 301: 805–809.
- Sarchiapone M, Carli V, Roy A, Iacoviello L, Cuomo C, Latella MC *et al*. (2008). Association of polymorphism (Val66Met) of brain-derived neurotrophic factor with suicide attempts in depressed patients. *Neuropsychobiology* 57: 139–145.
- Saxe MD, Battaglia F, Wang JW, Malleret G, David DJ, Monckton JE *et al*. (2006). Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. *Proc Natl Acad Sci USA* 103: 17501–17506.
- Scharfman H, Goodman J, Macleod A, Phani S, Antonelli C, Croll S (2005). Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. *Exp Neurol* 192: 348–356.
- Schmidt HD, Duman RS (2007). The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. *Behav Pharmacol* 18: 391–418.
- Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. *J Neurosci* 22: 3251–3261.
- Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM (1997). Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). *Pharmacol Biochem Behav* 56: 131–137.
- Snyder JS, Kee N, Wojtowicz JM (2001). Effects of adult neurogenesis on synaptic plasticity in the rat dentate gyrus. *J Neurophysiol* 85: 2423–2431.
- Soliman F, Glatt CE, Bath KG, Levita L, Jones RM, Pattwell SS *et al*. (2010). A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. *Science* 327: 863–866.
- Tsai SJ, Hong CJ, Liou YJ (2010). Effects of BDNF polymorphisms on antidepressant action. *Psychiatry Investig* 7: 236–242.
- Verhagen M, van der Meij A, van Deurzen PA, Janzing JG, Arias-Vasquez A, Buitelaar JK *et al*. (2010). Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. *Mol Psychiatry* 15: 260–271.
- Wang JW, David DJ, Monckton JE, Battaglia F, Hen R (2008). Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. *J Neurosci* 28: 1374–1384.

Supplementary Information accompanies the paper on the Neuropsychopharmacology website (<http://www.nature.com/npp>)